Literature DB >> 17526432

Matrix replenishment by intervertebral disc cells after chemonucleolysis in vitro with chondroitinase ABC and chymopapain.

Kazuhiro Chiba1, Koichi Masuda, Gunnar B J Andersson, Shigeki Momohara, Eugene J Thonar.   

Abstract

BACKGROUND CONTEXT: One of the advantages of chemonucleolysis for the treatment of a herniated intervertebral disc is the potential for the disc to self-repair. It has been suggested that the enzymes used for chemonucleolysis differentially affect the potential of the disc cells to promote repair.
PURPOSE: To test the ability of nucleus pulposus and anulus fibrosus cells to repair the extracellular matrix degraded in vitro by either chondroitinase ABC or chymopapain. STUDY
DESIGN: An alginate cell culture system was used to monitor the progress of matrix repair after chemonucleolysis in vitro.
METHODS: Rabbit nucleus pulposus or anulus fibrosus cells precultured for 10 days in alginate gel were briefly exposed to low concentrations of chondroitinase ABC or chymopapain and then returned to normal culture conditions for up to 4 weeks. At each time point, the contents of DNA and matrix macromolecules and proteoglycan synthesis were measured.
RESULTS: The DNA content of enzyme-treated alginate beads during the following 4 weeks of culture was higher in the chondroitinase ABC group than in the chymopapain group (NP, p<.01, and AF, p<.05). The content of proteoglycan in beads containing nucleus pulposus and anulus fibrosus cells in the chondroitinase ABC group was higher than that in the chymopapain group (NP and AF, p<.001). The rate of proteoglycan synthesis and the content of collagen did not, however, differ between those two groups.
CONCLUSIONS: Intervertebral disc cells exposed to chondroitinase ABC reestablish a matrix richer in proteoglycan than cells exposed to chymopapain. This may be because of differences in the substrate spectrum of each enzyme. Although these results cannot be translated directly to the in vivo situation, they suggest the possibility that cells in discs subjected to chondroitinase ABC-induced chemonucleolysis retain a greater ability to replenish their extracellular matrix with proteoglycans than cells in discs exposed to chymopapain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17526432     DOI: 10.1016/j.spinee.2006.09.005

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  6 in total

Review 1.  The structures and applications of microbial chondroitin AC lyase.

Authors:  Xiao-Man Fan; Li-Jian Zhou; Jia-Ying Huang; Ye-Wang Zhang
Journal:  World J Microbiol Biotechnol       Date:  2022-08-23       Impact factor: 4.253

Review 2.  Organ culture bioreactors--platforms to study human intervertebral disc degeneration and regenerative therapy.

Authors:  Benjamin Gantenbein; Svenja Illien-Jünger; Samantha C W Chan; Jochen Walser; Lisbet Haglund; Stephen J Ferguson; James C Iatridis; Sibylle Grad
Journal:  Curr Stem Cell Res Ther       Date:  2015       Impact factor: 3.828

Review 3.  Treatment of chronic low back pain - new approaches on the horizon.

Authors:  Nebojsa Nick Knezevic; Shane Mandalia; Jennifer Raasch; Ivana Knezevic; Kenneth D Candido
Journal:  J Pain Res       Date:  2017-05-10       Impact factor: 3.133

4.  Chemonucleolysis with Chondroitin Sulfate ABC Endolyase for Treating Lumbar Disc Herniation: Exploration of Prognostic Factors for Good or Poor Clinical Outcomes.

Authors:  Katsuhiko Ishibashi; Muneyoshi Fujita; Yuichi Takano; Hiroki Iwai; Hirohiko Inanami; Hisashi Koga
Journal:  Medicina (Kaunas)       Date:  2020-11-19       Impact factor: 2.430

Review 5.  Molecular therapy for disk degeneration and pain.

Authors:  Fackson Mwale
Journal:  Global Spine J       Date:  2013-07-12

6.  An Inflammatory Nucleus Pulposus Tissue Culture Model to Test Molecular Regenerative Therapies: Validation with Epigallocatechin 3-Gallate.

Authors:  Olga Krupkova; Marian Hlavna; Julie Amir Tahmasseb; Joel Zvick; Dominik Kunz; Keita Ito; Stephen J Ferguson; Karin Wuertz-Kozak
Journal:  Int J Mol Sci       Date:  2016-09-27       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.